Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
OBJECTIVE
To evaluate the contribution of preoperative serum tumor markers to manage borderline ovarian tumors (BOT).


METHODS
Retrospective multicentre study including 317 BOT. Serum tumor marker levels of CA125, CA19-9, CEA, and CA15-3 were determined by radio-immunoassay.


RESULTS
Among 181 women with serous BOT and 136 women with mucinous BOT, respectively 55 of 114 (48.2%) and 38 of 91 (41.8%) had at least one abnormal value. Women with preoperative tumor marker assays were more likely to have radical treatment (p=0.0001), full staging (p=0.004), and intra-operative histology (p<0.0001). Women with at least one abnormal tumor marker were more likely to undergo laparotomy (p=0.007), to have intra-operative histology (p=0.04) and complete staging (p=0.0008). In multivariate analysis, first-line laparoscopy was associated with abnormal tumor marker levels (OR=9.63; 95%CI=1.40-66.39; p=0.02), while laparotomy was associated with large tumors, bilateral tumors, and ascitis visible on sonography.


CONCLUSIONS
Serum tumor marker assays modified both preoperative assessment and surgical management of BOT.
Poncelet
C
C
Hôpital Tenon, AP-HP, CancerEst, Université Pierre et Marie Curie Paris VI, France.
Fauvet
R
R
Yazbeck
C
C
Coutant
C
C
Darai
E
E
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001201:Ascites / Q000209:etiology; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005629:Frozen Sections; D006801:Humans; D010535:Laparoscopy; D007813:Laparotomy; D016015:Logistic Models; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000150:complications / Q000601:surgery / Q000628:therapy*; D011863:Radioimmunoassay; D012189:Retrospective Studies; D012720:Severity of Illness Index
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1